Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “overweight” rating reissued by research analysts at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. They presently have a $440.00 price objective on the pharmaceutical company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 5.44% from the company’s current price. […]